Julia Stieglmaier

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Massimiliano Bonifacio et al. · Blood · 2018 · 810 citations · Full text

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

Andreas Viardot, Marie-Elisabeth Goebeler, Svenja Neumann et al. · Blood · 2016 · 358 citations · Full text

International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

Nicola Gökbuget, Hervé Dombret, Josep‐María Ribera et al. · Haematologica · 2016 · 205 citations · Full text

Mixed-phenotype Acute Leukemia, International Reference Analysis, Surgery +17

A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells

Christian Kellner, Joerg Bruenke, Julia Stieglmaier et al. · Journal of Immunotherapy · 2008 · 77 citations

Cancer Immunosurveillance, Sctb Ds, Immunology +15

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study

William K. Kelly, Daniel C. Danila, Chia‐Chi Lin et al. · Cancer Discovery · 2023 · 74 citations · Full text